文章：

[68Ga]-DOTATOC PET/CT体积参数反映胰腺神经内分泌肿瘤的转移潜能

[68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors

原文发布日期：28 April 2025

DOI: 10.3390/cancers17091487

类型: Article

开放获取: 是

英文摘要：

Background:[68Ga]-DOTATOC PET/CT is a valuable technique for identifying neuroendocrine tumors overexpressing somatostatin receptors; however, its diagnostic and prognostic utility for WHO low-grade pancreatic neuroendocrine tumors remains unclear. Therefore, we aimed to evaluate [68Ga]-DOTATOC uptake in well-differentiated pancreatic neuroendocrine tumors and determine its predictive capability for metastasis.Methods:Patients with pathologically diagnosed well-differentiated, non-functional pancreatic neuroendocrine tumors who underwent [68Ga]-DOTATOC PET/CT between 2015 and 2021 were included. Medical records and [68Ga]-DOTATOC PET/CT indices (maximal and mean standardized uptake values, somatostatin receptor-expressing tumor volume, and total lesion somatostatin receptor expression in pancreatic tumors) were retrospectively reviewed. Correlations between indices were analyzed to determine their collective diagnostic significance.Results:Among 93 patients who were pathologically diagnosed with pancreatic neuroendocrine tumors and underwent [68Ga]-DOTATOC PET/CT, 48 with well-differentiated, non-functional pancreatic neuroendocrine tumors without accompanying genetic syndromes were included. The pancreatic neuroendocrine tumors were classified as WHO grade 1 (n = 30, 62.5%) and grade 2 (n = 18, 37.5%), with tumors in 25% of the patients exhibiting initial metastases. A higher incidence of metastasis was observed in larger metabolically active tumors (somatostatin receptor-expressing tumor volume,p< 0.001; total lesion somatostatin receptor expression,p< 0.001).Conclusions:Volumetric parameters derived from [68Ga]-DOTATOC PET/CT correlates with initial metastasis in well-differentiated pancreatic neuroendocrine tumors.

摘要翻译： 

背景：[68Ga]-DOTATOC PET/CT是识别生长抑素受体过表达神经内分泌肿瘤的重要技术，但其对WHO低级别胰腺神经内分泌肿瘤的诊断与预后价值尚不明确。本研究旨在评估分化良好的胰腺神经内分泌肿瘤对[68Ga]-DOTATOC的摄取情况，并探究其对转移的预测能力。 方法：纳入2015年至2021年间经病理诊断为分化良好、无功能性胰腺神经内分泌肿瘤并接受[68Ga]-DOTATOC PET/CT检查的患者。回顾性分析病历资料及PET/CT指标（最大与平均标准化摄取值、生长抑素受体表达肿瘤体积、胰腺病灶总生长抑素受体表达量），通过指标相关性分析评估其综合诊断价值。 结果：在93例经病理确诊并接受PET/CT检查的胰腺神经内分泌肿瘤患者中，最终纳入48例分化良好、无功能性且不伴遗传综合征的患者。肿瘤分级为WHO 1级（30例，62.5%）和2级（18例，37.5%），其中25%的患者存在初始转移。研究发现代谢活跃的大体积肿瘤转移发生率显著增高（生长抑素受体表达肿瘤体积：p<0.001；病灶总生长抑素受体表达量：p<0.001）。 结论：[68Ga]-DOTATOC PET/CT衍生的体积参数与分化良好胰腺神经内分泌肿瘤的初始转移存在相关性。

原文链接：

[68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors